Treatment of Uncomplicated Cystitis with Fosfomycin and Trimethoprim-Sulfamethoxazole
Both fosfomycin and trimethoprim-sulfamethoxazole are appropriate first-line treatments for uncomplicated cystitis in women, but their use depends critically on local resistance patterns and specific clinical circumstances.
Trimethoprim-Sulfamethoxazole (TMP-SMX)
Use TMP-SMX (160/800 mg twice daily for 3 days) only when local resistance rates are below 20% or when the infecting organism is known to be susceptible 1. This threshold is based on expert consensus that demonstrates clinical cure rates drop dramatically when resistance exceeds this level—from 84% with susceptible organisms to only 41% with resistant strains 1.
Efficacy Profile
- Clinical cure rate: 93% (90-100%) 1
- Microbiological cure rate: 94% (91-100%) 1
- Early clinical cure consistently ranges from 86-100% across multiple trials 1
Key Limitations
The major caveat is resistance prevalence. If you recently prescribed TMP-SMX or fluoroquinolones to the patient, resistance risk increases substantially 1. In areas where resistance exceeds 20%, TMP-SMX should not be used empirically 1. The European Association of Urology no longer recommends it as first-choice treatment due to rising global resistance 1.
Common Side Effects
Rash, urticaria, nausea, vomiting, and hematologic effects 1
Fosfomycin Trometamol
Fosfomycin (3 g single dose) is appropriate first-line therapy due to minimal resistance (<1%) and low collateral damage, though it has slightly inferior microbiological efficacy compared to other agents 1, 2.
Efficacy Profile
- Clinical cure rate: 91% 1
- Microbiological cure rate: 80% (78-83%) 1—significantly lower than nitrofurantoin (86%, P=0.02) 1
- FDA-approved specifically for uncomplicated cystitis in women caused by E. coli and Enterococcus faecalis 2
Advantages
- Single-dose convenience improves compliance 2
- Minimal resistance development 3
- Effective against ESBL-producing and multidrug-resistant organisms 3
- No dosage adjustment needed in elderly, pregnant, or renally impaired patients 3
- Maintains urinary concentrations >100 µg/mL for 48 hours 3
Important Consideration for Renal Function
In patients with eGFR <60 mL/min, fosfomycin demonstrates superior efficacy to nitrofurantoin (16.0% vs 23.3% clinical failure, aOR 0.61) 4. This makes it particularly valuable in older patients or those with mild-to-moderate renal impairment.
Common Side Effects
Diarrhea, nausea, headache 1—generally well-tolerated with adverse event rates around 5.3% 1
Clinical Decision Algorithm
Choose TMP-SMX when:
- Local resistance rates are documented <20%
- Patient has not received TMP-SMX or fluoroquinolones recently
- Susceptibility testing confirms sensitivity
- Cost is a primary concern
Choose Fosfomycin when:
- Local TMP-SMX resistance exceeds 20%
- Patient compliance is questionable (single-dose advantage)
- Patient has eGFR <60 mL/min
- Concern exists for multidrug-resistant organisms
- Patient is pregnant (fosfomycin is safe in pregnancy) 3
- Previous antibiotic exposure increases resistance risk
Critical Pitfalls to Avoid
Do not use TMP-SMX empirically without knowing local resistance patterns—this is the most common prescribing error 5
Fosfomycin is NOT indicated for pyelonephritis or perinephric abscess 2—if symptoms suggest upper tract involvement, choose a different agent
If symptoms persist or recur within 4 weeks, obtain urine culture and assume the organism is resistant to the initial agent 6—retreat with a 7-day course of a different antibiotic
Both agents rank lower than nitrofurantoin for overall efficacy in uncomplicated cystitis when renal function is normal 7, but remain appropriate first-line choices based on resistance patterns and patient factors
The 2024 European guidelines and 2011 IDSA/ESCMID guidelines both support these agents as first-line options 6, 1, with the critical distinction that local epidemiology must guide empiric selection.